learn.nynjaetcPartner(s): Daria Boccher-Lattimore - Mailman School of Public Health
Hepatitis C (HCV) is a world-wide public health problem, the cause of cirrhosis and liver cancer, and the leading cause of liver transplantation. Until recently, treatments for HCV resulted in sustained suppression of the virus for only 50% of patients with the type of HCV most common in North America and Europe, genotype 1. In 2011, two new drugs, both direct-acting antivirals, were approved. These drugs are significantly more effective, but they are also complicated to prescribe, and patients must be carefully monitored for side effects. As the landscape of HCV treatments changes and progresses, health care providers must carefully consider which patients to treat immediately, which to wait to treat, and how to treat HCV in patients also infected with HIV.
CCNMTL partnered with the New York/New Jersey AIDS Education and Training Center to create and maintain learn.nynjaetc, an online learning effort to train health professionals to use new HCV drugs. The online course contains lectures by an expert on available HCV treatments, patient case studies, and interactive activities about treatment decisions. The course is intended for doctors and nurses in the New York/New Jersey region, but is open to anyone who wishes to learn more about HCV and available treatment options. The first release of the course in 2013 focused on the first two available direct-acting antiviral drugs. An update, released in 2014, covers the new range of direct-acting antivirals. Additional updates are anticipated as new treatments become available. Doctors who complete the course can receive Continuing Medical Education (CME) credits through Cornell University's CME program.
This project is funded by a grant from the U.S. Department of Health and Human Services Health Resources and Services Administration (HRSA).Access: Public
Released: July 2013